Introduction
Despite multimodality treatment strategies that combine surgery, chemotherapy, and radiotherapy, high grade gliomas are almost uniformly fatal (1) . One of the most important advances in the treatment of glioblastoma multiforme (GBM) over the past 20 years has been the introduction of temozolomide in combination with photon irradiation, followed by repetitive cycles of temozolomide. Although a significant subset of patients were survivors at 24 months, the overall increase in median lifespan of GBM patients was only 2.5 months (2) indicating that there still is an urgent need to develop innovative therapeutic approaches to treat brain tumors.
Experimental types of radiation therapy based on diverse physical principles, such as boron neutron capture therapy (BNCT) (3) and stereotactic synchrotron radiotherapy (SSR) (4) (5) (6) , are among those under investigation. Recently, we have reported on the therapeutic efficacy of intratumoral (i.t.) administration of carboplatin by convection-enhanced delivery (CED), followed by irradiation with either 80keV synchrotron X-rays (SSR) or 6MV (LINAC) photons for the treatment of the invariably fatal F98 rat glioma (6) . These studies showed that either type of chemo-radiotherapy produced significant prolongations of survival times of F98 glioma-bearing rats with subsets of long-term (>200 days) survivors (6) . Similar results were obtained with i.t. delivery of cisplatin by CED in combination with either synchrotron X-rays or 6MV photon irradiations 1 .
Cisplatin and carboplatin are highly effective anti-cancer drugs that have been used clinically to treat various malignancies (7) . The formation of platinum adducts with DNA can interfere with the repair of radiation-induced damage, which could explain the synergistic interaction between either cisplatin or carboplatin and ionizing radiation (8) . The clinical use of systematically administered platinated drugs to treat patients with brain tumors has been 1 Rousseau, J., Barth, R.F. and Elleaume, H. Unpublished data inserm-00410447, version 1 -25 Jan 2012 Rousseau 5 limited, by their systemic toxicity, but also by their poor ability to penetrate an intact bloodbrain barrier (BBB) in areas where there are microinvasive deposits of tumor (9) . Several approaches have been proposed to bypass the BBB and deliver anticancer drugs directly to the tumor, thereby increasing tumor drug concentrations and reducing the systemic toxicity.
These methods include CED of drugs via catheters placed into the tumor (10), or surgical implantation of drug-loaded polymer matrices in the brain (11) (12) (13) (14) . At least with chemosensitive tumors, there has been a clear relationship between the therapeutic response and increasing both the concentration and duration of exposure to carboplatin (12, 13) or cisplatin (15) . Using the RG2 model implanted in rats, Emerich et al. have shown that sustained delivery of carboplatin with biodegradable microspheres placed into the tumor produced significantly greater improvements in survival than equipotent bolus injections (13) . Similarly, Carson et al. have shown that carboplatin, delivered by osmotic-pumps into the brainstems of rats bearing F98-gliomas, significantly enhanced their survival (16) (17) (18) . In the present study, we have used carboplatin because it has been shown to be tumoricidal against gliomas both in vitro and in vivo (6, 7, 12, 19) and it was less neurotoxic than cisplatin (20) when delivered i.c. to rats and monkeys (12, 16, (20) (21) (22) . As described in detail below, we show that a 6-day i.t. infusion of carboplatin using osmotic pumps, combined with SSR was highly effective in prolonging survival and even curing F98 glioma-bearing rats.
Materials and Methods

Tumor model.
The F98 rat glioma simulates human GBMs in several important ways (23) , including its infiltrative pattern of growth within the brain and lack of a curative response to a variety of therapeutic modalities, except for BNCT (24) and our recent studies using i.c. delivery of cisor carboplatin combined with either synchrotron or megavoltage X-irradiation (5, 6). F98
inserm-00410447, version 1 -25 Jan 2012 were assembled and filled with carboplatin. The pumps were stored in the dark at 37°C for 24h prior to their use in a sterile solution of 0.9% saline. Seven days after tumor implantation the animals were anesthetized and the scalp re-opened. The bone wax was removed with a inserm-00410447, version 1 -25 Jan 2012 Rousseau 7 needle and the infusion cannula was advanced to a depth of 5mm through the hole made for tumor cell inoculation. The brain infusion kit was fixed in place with surgical glue and the pump was implanted in a subcutaneous pocket, in the mid-scapular region with a sufficient amount of catheter tubing to permit free motion of the animal's head and neck. The pumps were left in place from days 7 to 13, during which time the animals received an infusion of 144µL of either carboplatin (72µg, 194 nmol) or 5% dextrose, delivered at a flow rate of 1µL/h over 6 days, following which the pumps were removed.
X-irradiations.
Stereotactic synchrotron radiotherapy was carried out at the ESRF as previously described (4, 5) . A single 15 Gy dose was delivered on day 14 after tumor implantation, using monochromatic 78.8keV X-rays (80eV energy-bandwidth) (25) . The right cerebral hemisphere was centred on the rotation axis of the irradiation system and the beam was shaped to 10mm in width and 1mm in height. The dose was delivered while the rat was being rotated, and translating upwards between each of the adjacent 360º arcs so that the irradiated target volume encompassed a cylinder 10mm in diameter and 13 to 15mm in height. The Xray dose rate of 0.3Gy/s was determined using an ion chamber (Unidos, PTW, Freiburg, Germany). Contrast-enhanced imaging was performed by synchrotron computed tomography (SRCT), 15 to 18 days after implantation to confirm the presence of tumor.
Experimental groups.
Initially we evaluated the safety and efficacy of chemotherapy and radiotherapy treatments administered independently. In this study, 4,000 F98 cells were implanted into the brains of male Fischer rats weighing 230-260 g (Charles-River Laboratories, L'Abresles, France). The animals were stratified into four groups, and treated as indicated following tumor (day 0) implantation: Group 1: Untreated controls; Group 2 received a 6-day infusion inserm-00410447, version 1 -25 Jan 2012
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of carboplatin (144µL containing 72µg) beginning on day 7; Group 3 received a single fraction of 15 Gy on day 14; Group 4 (excipient control) received a 6-day infusion of 5% dextrose alone, which had been used for the dilution of carboplatin, beginning on day 7, in combination with a single 15 Gy dose of X-rays on day 14 (Table 1 ).
In the second study, we evaluated the combination of chemotherapy and X-irradiation.
The tumors were established by implanting 1,000 F98 cells i.c. The animals were randomized into 4 experimental groups, as follows: Group 5: Untreated-controls; Group 6: Chemotherapy alone; Group 7: X-irradiation alone; Group 8: Chemotherapy in combination with Xirradiation, 24 h after completion of infusion ( Table 2) .
Monitoring of clinical status and histopathology.
After therapy, the animals were weighed 3X per week and their clinical status was 
Statistical evaluation of survival data.
Kaplan-Meier survival curves were plotted for each group. Differences between groups
were assessed for statistical significance by means of the log-rank test (JMP®, SAS-Instituteinserm-00410447, version 1 -25 Jan 2012
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Inc., Cary, NC) or in the case of crossing survival curves, a modification of the Cox proportional hazards model was used to allow for non-proportional hazards (26) . Minimal statistical significance was defined at p<0.05. Those rats still alive at the end of the study were euthanized. The mean survival times (MST), standard errors (SE), and median survival times (MeST) were calculated using the euthanization date for rats that were still alive at the end of the study (censored data). Percent increased lifespan (%ILS) was determined relative to MST or MeST of untreated controls as previously described (6) . In those instances where censored data were used to calculate the MST, the "true" MST actually would have been larger. Although there are methods that can be used to estimate the "true" MST, this would have required a number of assumptions. Therefore, we have chosen to record the arithmetic mean even though this underestimated the true mean.
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Results
Therapeutic response following chemotherapy or X-irradiation alone.
Surgery for pump implantation was well tolerated. Although the animals lost ≤10% of their body weight within 7 days following initiation of chemotherapy, it subsequently was regained and clinically the animals appeared to be normal. Survival data and Kaplan-Meier plots for animals that received chemotherapy alone or X-irradiation alone are shown in Table 1 and Fig. 1 
Therapeutic response following chemo-radiotherapy.
Survival data following chemo-radiotherapy are summarized in Table 2 carboplatin alone, radiotherapy alone or chemo-radiotherapy, respectively. It is noteworthy that in the chemo-radiotherapy group, 8 of 11 rats (73%) were still alive at day 100.
Neuropathologic evaluation.
In the first experiment ( Table 1 ), rats that received 5% dextrose as an excipient control, followed by X-irradiation, all had large to massive tumors (TSI=3.13), the histology of which was similar to that of untreated animals, and to those that received X-irradiation alone. Six out of 9 animals that received carboplatin had large to massive tumors with central necrotic zone (TSI=2.44). One animal in this group had no evidence of tumor at the end of the study and was regarded as cured (Fig. 3B ).
In the second experiment ( Table 2) 
Discussion
In the present study, we have evaluated the therapeutic efficacy of prolonged i.c. infusions of carboplatin in combination with photon irradiation. First, we showed that infusions of carboplatin alone, and infusions of 5% dextrose in combination with X-irradiation, were well tolerated. As expected, the Kaplan-Meier survival plots of animals that had received 5% dextrose (vehicle for carboplatin infusions) in combination with X-irradiation was not statistically different from that of X-irradiated rats (p=0.51) and all of these animals died within <50 days following tumor implantation. The censored MST of 9 animals that had received carboplatin alone was 84±18 d. with one long-term survivor. In the second study, the group, which had received the same chemotherapeutic regimen, had a censored MST of 69±20 d. and 3 of 13 rats were long-term survivors (Table 2) . Chemotherapy alone improved the survival of F98 glioma-bearing rats, and this was further enhanced by the addition of Xirradiation. The combination of treatments was the most effective protocol with 55% longterm survivors and 73% of the rats alive at 100 days.
Our results demonstrate the therapeutic efficacy of i. (28), whereas in the present study, it was started on day 7 at a point in time that the tumor would not have been detectable
by SRCT or MRI. Therefore, it was not unexpected that the MSTs were longer since it is well recognized that the earlier treatment is initiated, the better the therapeutic response. This is supported by our own recent experimental data showing that if treatment with carboplatin, followed by 6MV X-irradiation was delayed until d. 17, at which time the tumor volume was ~60-80 mm 3 , the prolongation in MSTs were significantly less than those observed in animals whose treatment was started on d. 13 following implantation 3 . Firm conclusions can not be drawn on the fundamental mechanism of effects and further studies will be carried out to evaluate the importance of these various parameters.
To the best of our knowledge, only two clinical reports describe the direct i.c. infusion of platinated drugs for glioma treatment (14, 29) . Using 68 catheters, Bouvier et al. infused 8.2mg of cisplatin over 10 days to treat a patient with recurrent malignant glioma. There were no adverse side effects associated with, chemotherapy, catheter implantation or removal.
Although chemotherapy halted progression of the tumor, it recurred, and the patient died 6 months later (29) . In the other study, Sheleg et al. administered cisplatin, incorporated into biodegradable polymers, after subtotal resection of the GBM. Twenty polymer discs loaded 3 Yang, W., Barth, R.F. and Elleaume, H. Unpublished data.
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with cisplatin (1 mg/cm 2 ) were placed in the tumor bed. Two to three weeks after surgery, the patients received radiotherapy (60Gy). This combined treatment significantly increased the MST compared to that observed in patients who had received radiotherapy alone (427 versus 211 d., respectively) (14) .
A variety of systems has been proposed for the treatment of malignant brain tumors to deliver anti-cancer drugs locally in a sustained-released manner (11, 12, 15-18, 20, 30 reported that 5% carboplatin-loaded polymer (~0.5mg of drug), released over 8 to 13d., produced a threefold increase in MeST compared to controls. Systemic administration of carboplatin also significantly prolonged survival, but this was less effective than i.c. delivery (12) . Therapeutic efficacy was dose-related with an increasing number of early deaths associated with escalating doses of the drug up to 0.5mg (12) . In our study, the amount of carboplatin administered (72µg) was well below that used by Olivi et al. (12) ; it was well tolerated and resulted in 11% to 23% long-term survivors for chemotherapy alone (Tables 1   and 2 ). Carson et al. have reported that the infusion of carboplatin over a 7-day period with ALZET TM pumps at a dose of 0.1mg doubled the MST of Fischer rats bearing brainstem implants of either the F98-glioma or 9L gliosarcoma (16) . It is noteworthy that the brainstem was not damaged by direct infusion of 200µL of carboplatin (0.5mg/mL) at a flow rate of 1µL/h, and that there was no neurotoxicity until a lethal dose (≥1.0mg/mL) was administered (18) . Carboplatin also has been infused into the brainstem of monkeys over extended periods of time, and dose-dependent neurotoxicity only was observed with doses >400µg (22, 31) . Using atomic absorption spectroscopy, Guarnieri et al. have mapped the distribution of platinum after i.c. infusion of carboplatin using ALZET TM pumps into F98 glioma-bearing rats, with delivery parameters similar to those that we used. Platinum inserm-00410447, version 1 -25 Jan 2012 Rousseau 15 concentrations were maximal in brain sections corresponding to the infusion site with diminished amounts (1 to 5µg/g tissue) in sections that were 3mm from the point of infusion (17, 30) . However, this distribution pattern was observed in only half of the brains infused with rigid catheters such as the ones we have used. In contrast, the use of flexible catheters resulted in the expected drug distribution in all of the rats, in both normal and tumor-bearing animals. It was suggested that rigid catheters might result in backflow of the drug into the subdural space along the catheter path (17).
In conclusion, our data have demonstrated that intratumoral infusion of carboplatin, followed by either synchrotron, as in the present study, or as previously reported (6) 6MV LINAC photon irradiation, is highly effective for the treatment of F98 glioma bearing rats.
Studies to further improve this chemo-radiotherapeutic approach are in progress and will focus on further optimizing the drug delivery and radiation parameters, and on striking a balance between neurotoxicity and therapeutic efficacy. inserm-00410447, version 1 -25 Jan 2012 followed by X-irradiation ( ). The survivals of all treatment groups were significantly different from the untreated controls (p<0.001). The survival of the animals that received 5% dextrose infusion (excipient), followed by X-irradiation was not significantly different (p=0.51) from animals that received X-irradiation alone. Fig. 2 . Kaplan-Meier survival curves for F98 glioma-bearing rats after chemo-radiotherapy. The origin of the x-axis corresponds to tumor implantation. Group 5: untreated (×); Group 6: X-irradiation (-); Group 7: carboplatin alone ( ), or Group 8: in combination with X-irradiation ( ).The survivals of all treatment groups were significantly different from the untreated controls (p<0.0015). The survival of the animals that received carboplatin, followed by X-irradiation was significantly different from X-irradiated animals (p=0.0014) or those that received carboplatin alone (p=0.0472). Table 1 . Survival times of F98 glioma-bearing rats following chemotherapy or radiotherapy alone. Table 2 . Survival times of F98 glioma-bearing rats following chemotherapy with or without X-irradiation. inserm-00410447, version 1 -25 Jan 2012
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